Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
Date:3/11/2009

NEW YORK, March 11 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Friday, March 13, 2009 at 8:30 a.m. EDT to discuss the fourth quarter and year-end 2008 financial results. Michael S. Weiss, Chairman and Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-407-8289 (U.S.), 1-201-689-8341 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing our financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates, and a business development program designed to seek licensing and partnership opportunities for our current drug candidates. Keryx is headquartered in New York City.

    KERYX CONTACT:
    Lauren Fischer
    Director - Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5965
    E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
2. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
3. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. Keryx Biopharmaceuticals to Present at the Jefferies & Co. Healthcare Conference
6. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2008 Financial Results on Monday, May 12, at 8:30 A.M. EDT
8. Keryx Biopharmaceuticals to Present at the Deutsche Bank 33rd Annual Health Care Conference
9. Keryx Biopharmaceuticals Receives Nasdaq Notification
10. Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
11. Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2019)... ... October 10, 2019 , ... R3 Stem Cell announces ... course is October 18-19th, 2019 in Las Vegas with spots still open. , The ... training at several Ivy League universities including Cornell, Harvard and Dartmouth. He currently serves ...
(Date:10/8/2019)... ... October 08, 2019 , ... As Keck Graduate ... Maurer presented company executives with a set of recommendations to enhance supply chain ... insights from their TMP to a wider audience of industry leaders attending the ...
(Date:10/8/2019)... BOSTON (PRWEB) , ... October 08, 2019 , ... Today, ... U.K. of its lead development technology. Like the company’s precursor patent, approved in ... and accurate counting of tissue stem cells. Asymmetrex now markets the technology in ...
(Date:10/3/2019)... ... October 01, 2019 , ... Cheyenne is a beautiful ... Mimi, Cheyenne’s owner, owns and operates Rebel’s Run , which offers riding lessons ... amongst students and trail riding guests. Mimi describes her as her “go to ...
Breaking Biology Technology:
(Date:9/24/2019)... ... September 24, 2019 , ... ... portfolio of 3D porous titanium spinal implants with the expansion of its proprietary ... while more than tripling the number of cervical and lumbar instrumentation sets available ...
(Date:9/17/2019)... (PRWEB) , ... September 17, 2019 , ... ... a group of doctors, scientists and engineers from the Medical University of Warsaw, ... results of their work to-date in creating a neuroprosthetic system as part of ...
(Date:9/11/2019)... ... 10, 2019 , ... Newly released “Dream in Color” by ... offers a beautiful and thought-provoking journey through five chapters of human experience. , ... poems and other times, Whittaker wrote to Srinivasan’s paintings. Together, the dynamic watermedia ...
Breaking Biology News(10 mins):